Ambulatory inhalation therapy in obstructive lung diseases

Area of Science:

• Pulmonary medicine
• Pharmaceutical technology
• Environmental science

Background:

• Inhalation therapy is crucial for obstructive lung diseases, requiring specific particle sizes (2-5 microns) for airway penetration.
• Metered-dose inhalers (MDIs) are widely used but contain ozone-depleting chlorofluorocarbons (CFCs), necessitating reformulation.
• Patient misuse of MDIs significantly reduces drug deposition and clinical efficacy.

Purpose of the Study:

• To review the challenges associated with metered-dose inhalers (MDIs) and explore alternative inhalation devices.
• To discuss the limitations and reformulation requirements for MDI aerosols and newer inhalation technologies.

Main Methods:

• Literature review of inhalation devices for obstructive lung diseases.
• Analysis of MDI limitations, including environmental impact and user-dependent efficacy.
• Evaluation of alternative devices such as spacers, dry-powder inhalers (DPIs), and breath-actuated MDIs.

Main Results:

• MDIs face reformulation challenges due to CFC phase-out and significant patient misuse impacting efficacy.
• Alternative devices like spacers and DPIs improve drug delivery in some patients but have their own limitations.
• Reformulating MDI aerosols is complex and requires extensive safety and efficacy testing for new formulations.

Conclusions:

• The transition away from CFCs in MDIs requires careful consideration of reformulation feasibility and new device performance.
• Optimizing inhalation therapy for obstructive lung diseases necessitates addressing device design, patient technique, and formulation challenges.
• Further research and development are needed for effective, user-friendly, and environmentally sustainable inhalation drug delivery systems.